1. Home
  2. PMI vs INAB Comparison

PMI vs INAB Comparison

Compare PMI & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PMI

Picard Medical Inc.

HOLD

Current Price

$0.19

Market Cap

14.1M

Sector

N/A

ML Signal

HOLD

Logo IN8bio Inc.

INAB

IN8bio Inc.

N/A

Current Price

$1.42

Market Cap

13.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PMI
INAB
Founded
1981
2016
Country
United States
United States
Employees
75
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.1M
13.7M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
PMI
INAB
Price
$0.19
$1.42
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
30.4M
59.9K
Earning Date
06-18-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.11
$1.17
52 Week High
$13.68
$2.73

Technical Indicators

Market Signals
Indicator
PMI
INAB
Relative Strength Index (RSI) 40.20 40.72
Support Level $0.11 $1.35
Resistance Level $0.27 $1.85
Average True Range (ATR) 0.06 0.10
MACD 0.01 -0.02
Stochastic Oscillator 20.18 15.77

Price Performance

Historical Comparison
PMI
INAB

About PMI Picard Medical Inc.

Picard Medical Inc operates through its wholly owned subsidiary, a medical technology company focused on developing, manufacturing, and commercializing the SynCardia TAH, an implantable total artificial heart system. The company is engaged in designing, manufacturing, producing, supplying, marketing, and selling medical device products, including the SynCardia TAH, which is designed to assume the full function of a failed human heart in patients suffering from advanced heart failure. The SynCardia TAH replaces both the left and right ventricles as well as all four heart valves.

About INAB IN8bio Inc.

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.

Share on Social Networks: